Table 3.
Linagliptin pharmacokinetics after single doses of linagliptin 5 mg and 100 mg
| Non-compartmental parameters of linagliptin | Non-compartmental parameters of CD 1750 | |||||||
|---|---|---|---|---|---|---|---|---|
| Linagliptin 5 mg (n = 43) | Linagliptin 100 mg (n = 44) | Linagliptin 5 mg (n = 43) | Linagliptin 100 mg (n = 44) | |||||
| Parameter | gMean | gCV (%) | gMean | gCV (%) | gMean | gCV (%) | gMean | gCV (%) |
| AUC(0,24 h) (nmol l−1 h) | 101 | 25.1 | 1760 | 59.2 | 7.0 | 56.2 | 484 | 65.9 |
| Cmax (nmol l−1) | 7.05 | 28.5 | 267 | 66.6 | 1.1 | 59.7 | 59.7 | 57.9 |
| tmax (h)* | 2.00 | 0.5–3.0 | 1.52 | 0.5–6.0 | 3.0 | 1.0–4.0 | 3.0 | 1.0–6.0 |
*
For tmax, the median and range (min–max) are given. AUC(0, 24 h), Area under the plasma concentration–time curve from 0 to 24 h; Cmax, maximum observed plasma concentration; tmax, time of maximum observed concentration.